Vape boss says allowing 'strict' ads would help smokers quit

The CEO of British American Tobacco is advocating for stricter regulations on the vaping industry, suggesting that allowing more advertising could actually help smokers quit traditional cigarettes. This perspective highlights a potential shift in how vaping is viewed as a smoking cessation tool, which could lead to more smokers considering vaping as a viable alternative. It’s an important conversation as public health policies evolve to address smoking-related issues.

Spot gold has reached a historic milestone, surpassing $4,000 for the first time, reflecting a significant 50% increase this year, driven by central bank purchases and ongoing political instability. This surge in gold prices is noteworthy as it indicates a growing trend among investors seeking safe-haven assets amid economic uncertainty. Meanwhile, Vertu Motors has reported a £5.5 million profit hit due to disruptions from Jaguar Land Rover, highlighting challenges in the automotive sector. The retirement of Peter Hargreaves, co-founder of Hargreaves Lansdown, adds another layer of change in the investment landscape.

Mizuho has lowered its stock price target for Shift4 Payments due to international headwinds affecting the company's performance. This adjustment reflects concerns about the challenges Shift4 may face in global markets, which could impact its growth and profitability. Investors should pay attention to these developments as they could influence the stock's future trajectory.

RBC Capital has raised its price target for Select Medical's stock to $20, citing recent regulatory relief as a key factor. This adjustment reflects growing confidence in the company's future performance and highlights the positive impact of regulatory changes on its operations. Investors may see this as a promising sign for Select Medical's growth potential.

Mizuho has lowered its price target for Corteva's stock to $78 following the company's announcement of a stock split. This adjustment reflects concerns about the potential impact of the split on investor confidence and market performance. Investors should pay attention to how this change might affect Corteva's stock in the coming months, as it could influence trading strategies and overall market sentiment.

Zenas Biopharma has successfully licensed three promising autoimmune candidates from InnoCare, marking a significant step forward in their development pipeline. This collaboration not only enhances Zenas's portfolio but also underscores the growing importance of innovative treatments in the autoimmune space. The partnership is expected to accelerate research and bring new therapies to patients in need, highlighting the potential for improved health outcomes.